Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis

Clinical Infectious Diseases

Volumn 28, Issue 3, 1999, Pages 552-561

  Trollfors, Birger ^a,b,c   Taranger, John ^a,b   Lagergård, Teresa ^a,b   Sundh, Valter ^a,b   Bryla, Dolores A ^a,b   Schneerson, Rachel ^a,b   Robbins, John B ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Goteborg Pertussis Vaccine Trial   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; IMMUNOGLOBULIN G; PERTUSSIS TOXIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE TRANSMISSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VACCINATION;

EID: 0033007705     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515172     Document Type: Article

References (23)

1. 1. Sato Y, Arari H. Leucocytosis-promoting factor of Bordetella pertussis. Purification and characterization. Infect Immun 1972;6:899-904.
2. 2. Arai H, Sato Y. Separation and characterization of two distinct hemagglutinins contained in leucocytosis-promoting factor from Bordetella pertussis. Biochim Biophys Acta 1976;444:765-82.
3. 3. Granström G, Wretlind B, Salenstedt C-R, Granström M. Evaluation of serologic assays for diagnosis of whooping cough. J Clin Microbiol 1988;26:1818-23.
4. 4. Isacson J, Trollfors B, Hedvall G, Taranger J, Zackrisson G. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995;27:273-7.
5. 5. WHO meeting on case definitions of pertussis, Geneva, Switzerland, January 10-11, 1991. Document no. MIN/EPI/PERT/91.1. Geneva: World Health Organization, 1991.
6. 6. Trollfors B, Taranger J, Lagergård T, et al. A placebo-controlled trial of a pertussis toxoid vaccine. N Engl J Med 1995;333:1045-50.
7. 7. Taranger J, Trollfors B, Lagergård T, et al. Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 1997;16:180-4.
8. 8. Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol 1977;6:303-9.
9. 9. Houard S, Hackel C, Herzog A, Bollen A. Specific identification of Bordetella pertussis by the polymerase chain reaction. Res Microbiol 1989; 140:477-87.
10. 10. van der Zee A, Agterberg C, van Agterveld M, Peeters M, Mooi FR. Characterization of IS1001, an insertion sequence element of Bordetella parapertussis. J Bacteriol 1993;175:141-7.
11. 11. Taranger J, Trollfors B, Lagergård T. Clinical trials of a monocomponent pertussis toxoid vaccine (NICHD-Ptxd) - a technical report. Göteborg University, Göteborg, Sweden: Graphic Systems AB, 1995.
12. 12. Reizenstein E, Hallander H-O, Blackwelder WC, Kühn I, Ljungman M, Möllby R. Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 1995;183:279-90.
13. 13. Lind-Brandberg L, Wellinder-Olsson C, Lagergård T, Taranger J, Trollfors B, Zackrisson G. Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections. J Clin Microbiol 1998;36: 679-83.
14. 14. Zackrisson G, Krantz I, Lagergård T, et al. Antibody response to pertussis toxin in patients with clinical pertussis measured by enzyme-linked immunosorbent assay. Eur J Clin Microbiol Infect Dis 1988;7:149-54.
15. 15. Zackrisson G, Arminjon P, Krantz I, et al. Serum antibody response to filamentous hemagglutinin in patients with clinical pertussis measured by an enzyme-linked immunosorbent assay. Eur J Clin Microbiol Infect Dis 1988;7:764-70.
16. 16. Hallander HO, Storsaeter J, Möllby R. Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial. J Infect Dis 1991;163:1046-54.
17. 17. Burstyn DG, Baraff LJ, Peppler MS, Leake RD, Gerne J, Manclark CR. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun 1983;41: 1150-6.
18. 18. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsater J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
19. 19. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular and one whole-cell vaccine against pertussis. N Engl J Med 1996;334:341-8.
20. 20. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996;275:37-41.
21. 21. Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 1998;101:1-11.
22. 22. Wassilak SGF, Anemona A, Giuliano M, Giammanco A. Differences by antigen in seroconversion: sensitivity, specificity, and bias in the serological confirmation of pertussis. Dev Biol Stand 1997;89:221-8.
23. 23. Granström G, Granström M, Anderson M, et al. Bordetella pertussis lipopolysaccharide as antigen in ELISA for serological diagnosis of whooping cough. Serodiagnosis and Immunotherapy in Infectious Diseases 1990;4:151-8.